A retrospective review of gender-affirming hormone therapy was conducted in 101 transgender boys followed in the pediatric endocrine clinic. Eighty-seven percent were postmenarchal at the initial visit. Of the 44% prescribed gonadotropin-releasing hormone analogs (GnRHas), insurance coverage was denied in 34% and an average of 4.5 months elapsed before treatment could be started in the remainder. Patients prescribed GnRHas were younger than those who were not, 13.7±2.1 versus 15.5±2.0 years, p<0.001. Continued menstrual bleeding was reported by patients receiving testosterone alone at doses ranging from 50 to 200 mg every 2 weeks.
Get full access to this article
View all access options for this article.
References
1.
RistoriJ, SteensmaTD. Gender dysphoria in childhood. Int Rev Psychiatry, 2016; 28(1):13–20; doi: 10.3109/09540261.2015.1115754
2.
HembreeWC, Cohen-KettenisPT, GoorenL, et al.Endocrine treatment of gender-dysphoric/gender-incongruent persons: An endocrine society clinical practice guideline. J Clin Endocrinol Metab, 2017; 102(11):3869–3903; doi: 10.1210/jc.2017-01658
3.
ColemanE, BocktingW, BotzerM, et al.Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgend, 2012; 13(4):165–232; doi: 10.1080/15532739.2011.700873
4.
RaffertyJ, Committee on Psychosocial Aspects of Child and FamilyHealth, Committee onAdolescence, et al.Ensuring comprehensive care and support for transgender and gender-diverse children and adolescents. Pediatrics, 2018; 142(4):e20182162; doi: 10.1542/peds.2018-2162
5.
RamosGGF, MengaiACS, DaltroCAT, et al.Systematic review: Puberty suppression with GnRH analogues in adolescents with gender incongruity. J Endocrinol Invest, 2021; 44(6):1151–1158; doi: 10.1007/s40618-020-01449-5
6.
GiordanoS. Lives in a chiaroscuro. Should we suspend the puberty of children with gender identity disorder? J Med Ethics, 2008; 34(8):580–584; doi: 10.1136/jme.2007.021097
7.
van de GriftTC, van GelderZJ, MullenderMG, et al.Timing of puberty suppression and surgical options for transgender youth. Pediatrics, 2020; 146(5):e20193653; doi: 10.1542/peds.2019-3653
8.
NosAL, KleinDA, AdirimTA, et al.Association of gonadotropin-releasing hormone analogue use with subsequent use of gender-affirming hormones among transgender adolescents. JAMA Netw Open, 2022; 5(11):e2239758; doi: 10.1001/jamanetworkopen.2022.39758
9.
van der LoosMATC, HannemaSE, KlinkDT, et al.Continuation of gender-affirming hormones in transgender people starting puberty suppression in adolescence: A cohort study in the Netherlands. Lancet Child Adolesc Health, 2022; 6(12):869–875; doi: 10.1016/S2352-4642(22)00254-1
10.
O'ConnellMA, NguyenTP, AhlerA, et al.Approach to the patient: Pharmacological management of trans and gender-diverse adolescents. J Clin Endocrinol Metab, 2022; 107(1):241–257; doi: 10.1210/clinem/dgab634
11.
CartayaJ, LopezX. Gender dysphoria in youth: A review of recent literature. Curr Opin Endocrinol Diabetes Obes, 2018; 25(1):44–48; doi: 10.1097/MED.0000000000000378
12.
ChewD, AndersonJ, WilliamsK, et al.Hormonal treatment in young people with gender dysphoria: A systematic review. Pediatrics, 2018; 141(4):e20173742; doi: 10.1542/peds.2017-3742
13.
StoffersIE, de VriesMC, HannemaSE. Physical changes, laboratory parameters, and bone mineral density during testosterone treatment in adolescents with gender dysphoria. J Sex Med, 2019; 16(9):1459–1468; doi: 10.1016/j.jsxm.2019.06.014
14.
HandlerT, HojillaJC, VargheseR, et al.Trends in referrals to a pediatric transgender clinic. Pediatrics, 2019; 144(5):e20191368; doi: 10.1542/peds.2019-1368
15.
ChenM, FuquaJ, EugsterEA. Characteristics of referrals for gender dysphoria over a 13-year period. J Adolesc Health, 2016; 58(3):369–371; doi: 10.1016/j.jadohealth.2015.11.010
16.
Pullen SansfaçonA, Temple-NewhookJ, Suerich-GulickF, et al.The experiences of gender diverse and trans children and youth considering and initiating medical interventions in Canadian gender-affirming speciality clinics. Int J Transgend, 2019; 20(4):371–387; doi: 10.1080/15532739.2019.1652129
17.
StevensJ, Gomez-LoboV, Pine-TwaddellE. Insurance coverage of puberty blocker therapies for transgender youth. Pediatrics, 2015; 136(6):1029–1031; doi: 10.1542/peds.2015-2849
18.
MahfoudaS, MooreJK, SiafarikasA, et al.Gender-affirming hormones and surgery in transgender children and adolescents. Lancet Diabetes Endocrinol, 2019; 7(6):484–498; doi: 10.1016/S2213-8587(18)30305-X
